New Enterprise Associates 14, L.P.
CIK 1544328 · last filed 2026-08-14
New Enterprise Associates 14, L.P. is a corporate insider who has filed 15 SEC Form 4 insider transactions across 7 companies since 2015. The most recent filing, for SYBX, was dated Aug 14, 2026. Across all open-market trades the lifetime net is −$193.1M, making them a net seller over the disclosed history. The firm reports its address in Timonium, MD. 58 SEC filings were submitted jointly with NEA 14 GP, LTD.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
7
15
-$193.11M
Filer Profile
SUITE 600
TIMONIUM, MD 21093
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SYNLOGIC, INC. (SYBX) Delisted | Director | — | $0.69 | — | $0 | 1 | 2026-08-14 |
| Oyster Point Pharma, Inc. (OYST) Delisted | 10%+ Owner | 0 | $11.17 | $0 | $0 | 1 | 2023-01-04 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | 10%+ Owner | 826,400 | $14.59 | $12.06M | -$2.89M | 2 | 2022-01-25 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | 10%+ Owner | 238,381 | $29.08 | $6.93M | $0 | 2 | 2020-09-16 |
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 3,179,544 | $1.07 | $3.40M | $2.00M | 1 | 2018-04-23 |
| APPN | 10%+ Owner | 0 | $38.37 | $0 | -$198.22M | 3 | 2018-02-15 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 1,499,166 | — | — | $6.00M | 1 | 2015-10-06 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-14 | SYNLOGIC, INC. (SYBX) Delisted | Mixed | — | $0 | EDGAR |
| 2025-08-15 | — | Notice (144) | −13,829,778 | -$981.9K | EDGAR |
| 2025-08-15 | — | Notice (144) | −3,250,000 | -$230.8K | EDGAR |
| 2024-07-17 | — | Notice (144) | −2,723,700 | -$4.41M | EDGAR |
| 2024-04-19 | — | Notice (144) | −4,539,242 | -$7.45M | EDGAR |
| 2023-01-04 | Oyster Point Pharma, Inc. (OYST) Delisted | U | −41,477,009 | $0 | EDGAR |
| 2022-01-25 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −1,076,464 | -$1.62M | EDGAR |
| 2021-12-29 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −539,416 | -$1.28M | EDGAR |
| 2020-09-16 | Mersana Therapeutics, Inc. (MRSN) Delisted | Other (J) | −2,000,000 | $0 | EDGAR |
| 2020-04-13 | Mersana Therapeutics, Inc. (MRSN) Delisted | Other (J) | −4,000,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.